Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French society of rheumatology registry

Arthritis Care and Research

Volumn 66, Issue 9, 2014, Pages 1289-1295

  Payet, Sarah ^a   Soubrier, Martin ^a   Perrodeau, Elodie ^b   Bardin, Thomas ^c   Cantagrel, Alain ^d   Combe, Bernard ^e   Dougados, Maxime ^f   Flipo, René Marc ^g   Le Loët, Xavier ^h   Shaeverbeke, Thierry ⁱ   Ravaud, Philippe ^b   Gottenberg, Jacques Eric ^j   Mariette, Xavier ^k  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^c Bicêtre Teaching Hospital   (France)

^d HÔTEL DIEU   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f CHU PURPAN   (France)

^g MONTPELLIER UNIVERSITY HOSPITAL   (France)

^h Institut Cochin   (France)

ⁱ EQUIPPE Universities of Lille and IRES   (France)

^j ROUEN UNIVERSITY HOSPITAL   (France)

^k Orthopaedic Surgery and Traumatology Department   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CORTICOSTEROID THERAPY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; INFECTION; INFECTIOUS ARTHRITIS; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POSTOPERATIVE INFECTION; PROSTHESIS INFECTION; REGISTER; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; SEPTICEMIA; SKIN CANCER; SKIN INFECTION; SOLID TUMOR; TREATMENT RESPONSE; UROGENITAL TRACT INFECTION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84906706656     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22314     Document Type: Article

References (25)

1. Soubrier M, Mathieu S, Payet S, Dubost JJ, Ristori JM,. Elderly-onset rheumatoid arthritis. Joint Bone Spine 2010; 77: 290-6.
2. Tutuncu Z, Kavanaugh A,. Rheumatic disease in the elderly: rheumatoid arthritis. Rheum Dis Clin North Am 2007; 33: 57-70.
3. Villa-Blanco JI, Calvo-Alen J,. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging 2009; 26: 739-50.
4. Ogasawara M, Tamura N, Onuma S, Kusaoi M, Sekiya F, Matsudaira R, et al. Observational cross-sectional study revealing less aggressive treatment in Japanese elderly than nonelderly patients with rheumatoid arthritis. J Clin Rheumatol 2010; 16: 370-4.
5. Tutuncu Z, Reed G, Kremer J, Kavanaugh A,. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006; 65: 1226-9.
6. Avina-Zubieta JA, Abrahamowicz M, De Vera MA, Choi HK, Sayre EC, Rahman MM, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford) 2013; 52: 68-75.
7. Moghadam-Kia S, Werth VP,. Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol 2010; 49: 239-48.
8. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 928-34.
9. Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF,. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 906-10.
10. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dorner T, et al, and the Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-20.
11. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al, and the AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62: 2625-32.
12. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72: 329-36.
13. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-80.
14. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al, the BSRBR Control Centre Consortium, and the British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-31.
15. Bathon JM, Fleischmann RM, van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol 2006; 33: 234-43.
16. Fleischmann R, Baumgartner SW, Weisman MH,. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006; 65: 379-84.
17. Koller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS,. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology (Oxford) 2009; 48: 1575-80.
18. Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, et al. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. Medicine (Baltimore) 2011; 90: 139-45.
19. Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 353-61.
20. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: 1754-64.
21. Genevay S, Finckh A, Ciurea A, Chamot AM, Kyburz D, Gabay C, for the Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. Tolerance and effectiveness of anti-tumor necrosis factor α therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2007; 57: 679-85.
22. Radovits BJ, Kievit W, Fransen J, van de Laar MA, Jansen TL, van Riel PL, et al. Influence of age on the outcome of antitumour necrosis factor α therapy in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1470-3.
23. Curtis JR, Xie F, Chen L, Muntner P, Grijalva CG, Spettell C, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2012; 64: 1480-9.
24. Smolen JS, Martin-Mola E, Rubbert-Roth A, Beaulieu A, Davies C, John A, et al. Efficacy and safety of tocilizumab in rheumatoid arthritis in patients above and below 65 years of age with an inadequate response to DMARDs [abstract]. Ann Rheum Dis 2008; 67 Suppl II: 338.
25. Filippini M, Bazzani C, Favalli EG, Marchesoni A, Atzeni F, Sarzi-Puttini P, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol 2010; 38: 90-6.